1	A SIMPLE COLORIMETRIC MOLECULAR DETECTION OF NOVEL				
2	CORONAVIRUS (COVID-19), AN ESSENTIAL DIAGNOSTIC TOOL FOR				
3	PANDEMIC SCREENING				
4	Pazhanimuthu Annamalai, Madhu Kanta, Pazhanivel Ramu, Baskar Ravi,				
5	Kokilavani Veerapandian and Rengarajan Srinivasan*				
6	Aura Biotechnologies Private Limited, Survey No. 270/1, Plot No. 1 & 2, Galaxy				
7	Road, Ayanambakkam, Chennai – 600 095, Tamil Nadu, India.				
8					
9	*Corresponding Author				
10	Dr Rengarajan Srinivasan, Chief Scientific Officer, Aura Biotechnologies Private				
11	Limited, Survey No. 270/1, Plot No. 1 & 2, Galaxy Road, Ayanambakkam,				
12	Chennai – 600 095,Tamil Nadu, INDIA.				
13	E-mail: rengarajan.s@aurabiotech.com, Phone: +91 (0) 79042 51771				
14					
15	Short Title: SARS-CoV-2 Detection by LAMP and RT-LAMP				
16					
17	Key Words: SARS-CoV-2 infection; rapid diagnosis; LAMP assay; point of care				
18	detection				
19					
20					
21					
22					

#### 23 Abstract

The recent outbreak of the newly emerged novel coronavirus (SARS-CoV-2) 24 presents a big challenge for public health laboratories as virus isolates are not 25 available while there is an increasing evidence that the epidemic is more 26 widespread than initially thought, as well as spreading internationally across 27 borders through travellers does already happen warranting a methodology for the 28 rapid detection of the infection to control SARS-CoV-2. Aim: We intended to 29 develop and deploy a robust and rapid diagnostic methodology using LAMP 30 assay for use in point of care settings to detect SARS-COV-2 infection. 31 Methodology: In the present study, we have developed a validated rapid 32 33 diagnostic procedure to detect SARS-CoV-2 using LAMP assay, its design relying on isothermal amplification of the nucleic acids of the SARS-CoV-2. 34 35 Results: The LAMP assay developed detects SARS-CoV-2 infection rapidly with high sensitivity and reliability. The data generated by LAMP assay were 36 comparable and at par with the data generated by real-time PCR method. 37 Conclusion: The present study demonstrates that the LAMP assay developed 38 was a rapid, reliable, sensitive and cost effective method to detect SARS-CoV-2 39 infection in a point of care as well as in laboratory settings. 40

41

42

## 44 Introduction

Novel coronavirus (SARS-CoV-2) infection is thought to have spread to human 45 populations from the animal kingdom in November or December, 2019, as 46 implied by the phylogeny of genomic sequences obtained from early cases.<sup>1</sup> The 47 genetic epidemiology implies that from the commencement of December, 2019, 48 when the first cases were retrospectively found out in Wuhan, the increase 49 in infection has been almost entirely driven bv human-to-human 50 transmission and not as the result of persistent spillover. There was a colossal 51 transmission of the virus within a matter of weeks in Wuhan, and people in the 52 resulting links of transmission spread infection by national and international travel 53 54 during the holidays of Chinese new year.

55 SARS-CoV-2 appears to have different epidemiological characteristics when 56 compared to SARS-CoV-1. SARS-CoV-2 replicates efficiently in the upper 57 respiratory tract and seems to cause less abrupt onset of symptoms, comparable 58 to the conventional human coronaviruses that are a major reason of common 59 colds in the winter season.<sup>2</sup> Infected individuals, during the prodrome period, 60 produce a large quantity of virus in the upper respiratory tract, are mobile, and 61 carried on routine day-to-day activities, contributing to the spread of infection.

SARS-CoV-2 also has affinity for cells in the lower respiratory tract and can replicate there also, causing radiological evidence of lesion in the lower respiratory tract in patients who do not exhibit clinical pneumonia.<sup>1</sup> There appear to be three key patterns of the clinical route of infection: mild illness with upper

respiratory tract presenting symptoms; non-life-threatening pneumonia; and 66 severe pneumonia with acute respiratory distress syndrome (ARDS) that begins 67 with mild symptoms for 7 - 8 days and then advances to rapid deterioration 68 requiring advanced life support.<sup>3</sup> At present, SARS-CoV-2 appears to spread 69 from person to person by the same mechanism as other common cold or 70 influenza viruses *i.e.*, face to face contact with a sneeze or cough or due to 71 contact with secretions of people who are infected. The role of faecal - oral 72 transmission is yet to be established in SARS-CoV-2 but was found to occur 73 during the SARS outbreak.<sup>4</sup> 74

A possible scenario based on the existing evidence now is that the newly identified SARS-CoV-2, similar to the seasonal influenza virus, is causing mild and self-limiting disease in majority of people who are infected, with severe disease more possibly among aged people or those with comorbidities, such as diabetes, pulmonary disease, and other chronic conditions.

Viruses of the family Coronaviridae have a single-strand, positive-sense RNA 80 genome of 26 – 32 kilo bases in length.<sup>5</sup> Coronaviruses have been reported in a 81 number of avian hosts,<sup>6, 7</sup> as well as in a variety of mammals, including camels, 82 bats, mice, dogs, and cats. Novel mammalian coronaviruses are now regularly 83 been identified.<sup>5</sup> For instance, an HKU2-related coronavirus of bat origin was 84 identified to be responsible for a fatal acute diarrhea syndrome in pigs in the year 85 2018.<sup>8</sup> Amongst several corona viruses that are pathogenic to humans, most are 86 associated with mild clinical symptoms,<sup>5</sup> with two notable exceptions: severe 87

acute respiratory syndrome (SARS) coronavirus (SARS-CoV), a novel beta-88 coronavirus that emerged in Guangdong, southern China, in November, 2002<sup>9</sup> 89 and resulted in more than 8000 human infections and 774 deaths in 37 countries 90 during 2002 – 2003;<sup>10</sup> and Middle East respiratory syndrome (MERS) 91 coronavirus (MERS-CoV), which was first detected in Saudi Arabia in 2012<sup>11</sup> and 92 was accountable for 2494 laboratory-confirmed cases of infection and 858 93 casualties since September, 2012, including 38 deaths following a single 94 introduction into South Korea.<sup>12, 13</sup> In late December, 2019, several patients 95 with viral pneumonia were found to be epidemiologically associated with the 96 Huanan seafood market in Wuhan, in the Hubei province of China, where a 97 number of non-aquatic animals such as birds and rabbits were also on sale 98 before the outbreak. A novel, human-infecting coronavirus,<sup>14, 15</sup> temporarily 99 named 2019 novel coronavirus (2019-nCoV), was identified with use of 100 next-generation sequencing. As of Jan 28, 2020, China has reported more than 101 5900 confirmed cases as well as more than 9000 suspected cases of 2019-nCoV 102 infection across 33 Chinese provinces or municipalities, with 106 casualties. 103 Furthermore, 2019-nCoV has now also been reported in Thailand, Japan, South 104 Korea, Malaysia, Singapore, and the USA. People in the health care industry are 105 at high risk of infection, and health-care-associated intensification of transmission 106 is of great concern as is always the case for emerging infections. Most of the 107 infected patients had a high fever and some had dyspnoea, with chest 108 radiographs revealing invasive lesions in both lungs.<sup>1, 16</sup> Non-pharmaceutical 109

interventions remain vital for the management of SARS-CoV-2 infection as thereis no licensed vaccine or coronavirus antiviral available.

At present, for the qualitative detection of the SARS-CoV-2 in nasopharyngeal 112 swabs, alveolar lavage fluid, sputum, and blood samples, reverse transcription-113 PCR (RT-PCR) kits are being rapidly developed.<sup>17</sup> Nevertheless, RT-PCR tests 114 require skilled personnel and well-equipped laboratories that restrict this 115 detection method at point-of-care centres and smaller clinics. The increasing 116 number of suspected cases surpasses the capacity of many hospitals, leaving 117 118 many patients untested thereby challenging the control of spread of the disease. A rapid, point-of-care molecular diagnostics for the SARS-CoV-2 detection is the 119 120 urgent need of the hour to address the crisis. Therefore, in the present study we have developed a simple closed-tube molecular diagnostic test for SARS-CoV-2 121 that can be carried out at point-of-care centres and small clinics by minimally 122 trained personnel without the need for sophisticated equipments. In the present 123 study, we report the development of a rapid and reliable molecular detection 124 method to identify the newly emerged coronavirus SARS-CoV-2 by loop-125 mediated isothermal amplification assay. 126

- 127
- 128
- 129
- 130

## 132 Methods

133 Procurement of RNA Clones of Genes of Interest

The RNA Clones of genes of interest, *N* gene, *ORF* gene and the internal control gene, RNAse P were procured as clones from GenScript, USA. The sequences of RNA clones of the genes of interest are as follows:

- 137 N Gene:
- 138 cacccgcaatcctgctaacaatgctgcaatcgtgctacaacttcctcaaggaacaacattgccaaaaggcttcta
- 139 cgcagaagggagcagaggcggcagtcaagcctcttctcgttcctcatcacgtagtcgcaacagttcaagaaatt
- 141 gctgcttgacagattgaaccagcttgagagcaaaatgtctggtaaaggccaacaacaacaaggccaaactgt
- 142 cactaagaaatctgctgctgaggcttctaagaagcctcggcaaaaacgtactgccactaaagcatacaatgtaa
- 143 cacaagct

144 ORF Gene

152

154 RNaseP Gene

atggcggtgtttgcagatttggacctgcgagcgggttctgacctgaaggctctgcgcggacttgtggagacagcc 155 gctcaccttggctattcagttgttgctatcaatcatatcgttgactttaaggaaaagaaacaggaaattgaaaaacc 156 157 agtagctgtttctgaactcttcacaactttgccaattgtacagggaaaatcaagaccaattaaaattttaactagatt aacaattattgtctcggatccatctcactgcaatgttttgagagcaacttcttcaagggcccggctctatgatgttgttg 158 159 gagaaactaccattttacttcaaaagacctcctattaatgtggcgattgaccgaggcctggcttttgaacttgtctat 160 agccctgctatcaaagactccacaatgagaaggtatacaatttccagtgccctcaatttgatgcaaatctgcaaa 161 162 ggaaagaatgtaattatatctagtgctgcagaaaggcctttagaaataagagggccatatgacgtggcaaatct aggettgetgtttgggetetetgaaagtgacgccaaggetgeggtgtccaccaactgecgageagegettetecat 163 164 ggagaaactagaaaaactgcttttggaattatctctacagtgaagaaacctcggccatcagaaggagatgaag 165 attgtcttccagcttccaagaaagccaagtgtgagggctga

166

167 LAMP Primers

The LAMP primers (Table 1) targeting genes of interest, N and ORF genes and the internal control RNaseP gene were designed using Primer Explorer ver. 5 (http://primerexplorer.jp/lampv5e/index.html). These primers were synthesized by Eurofins Scientific India Pvt. Ltd, Bangalore, India). The primers used for the amplification of the genes of interest and the internal control gene are given in Table 1.

174

176 Colorimetric LAMP Reaction

The LAMP reaction was performed in a total of 25 µl reaction volume using para-177 cresol dye-based AURA 2 X LAMP master mix (15 µl) that contained each of the 178 four dNTPs (1.4 mM), thermo stable reverse transcriptase (1 µl), AURA Bst 179 polymerase (8 U), the primers (1.6 µM FIP and BIP; 0.4 µM LB and LF; 0.2 µM 180 F3 and B3) and 120 µM para-cresol dye. The target RNA at different copy 181 numbers (10<sup>-6</sup> to 10<sup>0</sup>) was added to the master mix and the final reaction volume 182 was made up to 25 µl with water. NTC had all the reaction components except 183 the target RNA. The reaction was carried out at 65°C for 30 minutes. 184

185

## 186 Real-Time LAMP Reaction

The real-time LAMP reaction was performed in a total of 25 µl reaction volume 187 using para-cresol dye-based AURA 2 X LAMP master mix (15 µl) that contained 188 each of the four dNTPs (1.4 mM), thermo stable reverse transcriptase (1  $\mu$ l), 189 AURA Bst polymerase (8 U), the primers (1.6 µM FIP and BIP; 0.4 µM LB and 190 LF; 0.2 µM F3 and B3) and 120 µM para-cresol dye as well as 1 X Evagreen and 191 1X ROX reference dyes. The target RNA at different copy numbers  $(10^{-6} - 10^{0})$ 192 was added to the master mix and the final reaction volume was made up to 25 µl 193 with water. NTC had all the reaction components except the target RNA. The 194 fluorescent signals were observed automatically by MxPro 3000P Real-Time 195 PCR System (Agilent Technologies, New York, USA). The Ct values obtained for 196

different copy numbers  $(10^{-6} - 10^{0})$  of the N and ORF target RNAs as well as for internal control RNaseP RNA were given in Table 2.

199

## 200 Role of the Funding Source

The present study was not supported by funding agency / organization.

202

## 203 **Results and Discussion**

204 Real-Time LAMP Detection of SARS-CoV-2

205 The S-type amplification curves demonstrated a positive result, while the smooth straight line represents the NTC. From the amplification curves, it is evident that 206 207 the set of primers used for the specific detection of the N gene, ORF gene and the internal control RNaseP gene in the present study 208 demonstrated increased fluorescence signals in the presence of the templates of 209 the respective genes only and no fluorescence signals was observed for NTC 210 (Fig. 1A, 1B, 1C). The sensitivity was found to be high the viral RNA is detected 211 even up to 10 copy number with good specificity. 212

The present study was aimed at developing a LAMP assay specifically for the detection of *N* and *ORF* genes of SARS-CoV-2 (COVID-19) and hence LAMP primers were designed for the amplification of these two genes along with the internal control RNaseP gene using the Primer Explorer (ver. 5) software. The designed primers were validated by performing a real-time LAMP assay with the clones of the *N* and *ORF* gene as well the internal control RNaseP gene and from the amplifications curves generated in the assay, it is observed that the amplicons generated were respective to each of N, ORF and RNaseP genes from the LAMP reaction mix that contained the respective target DNAs and nothing got amplified from the NTC reaction mix thereby demonstrating that the designed primers are the valid ones to use for the detection of SARS-CoV-2 infection in suspected / affected individuals.

225 Colorimetric LAMP Detection of SARS-CoV-2

The gradual change in the colour from pink (NTC) to yellow (target DNAs  $10^{\circ}$ ) was visually evident as a result of no binding of the target genes' (N and ORF genes as well as the internal control gene RNaseP) specific primers in NTC LAMP reaction mix to the gradual increased binding of specific primers to the target genes (N and ORF genes as well as the internal control gene RNaseP) of interest in 10-fold serial dilution ( $10^{\circ} - 10^{-6}$ ) of LAMP reaction mixes (Fig. 2A, 2B, 2C).

In the current study, at the end of the LAMP assay, we observed a dilutiondependent colour difference (*i.e.*, pink to yellow) in the reactions mixes that contained low to high copy numbers of the target DNAs *N* and *ORF* of SARS-CoV-2 as well as the internal control RNaseP gene, thus suggesting that the target DNAs specific primers designed got bound to the specific target DNAs and amplified the same to several magnitude.

## 240 **Conclusion**

To conclude, the present study has demonstrated that SARS-CoV-2 infection in 241 humans can be detected by LAMP and RT-LAMP assays by targeting the N and 242 ORF genes of SARS-CoV-2 with high sensitivity and specificity. In addition, our 243 study has also confirmed that LAMP assay is a potential, suitable, cost effective 244 and time saving specific method for the rapid diagnosis of SARS-CoV-2 infection 245 and also aids to a great extent in the screening of this pandemic infection, 246 surveillance as well as combating the spread of SARS-CoV-2 infection at the 247 248 point of risk.

249

## 251 **References**

- I. GISAID: Genomic epidemiology of BetaCoV 2019–2020.
   https://www.gisaid.org/epiflu-applications/next-betacov-app/ (accessed Feb
   11, 2020).
- Chan JF-W, Yuan S, Kok, K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; published online Jan 24. https://doi.org/10.1016/S0140-6736(20)30154-9.
- 259 3. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory
   260 syndrome. N Engl J Med 2003; 349: 2431–41.
- 4. European Centre for Disease Prevention and Control. Severe acute
   respiratory syndrome—Annual Epidemiological Report 2016 (2014 data).
- Dec 30, 2016. https://www.ecdc.europa.eu/en/publications-data/severe-
- acute-respiratory-syndrome-annual-epidemiological-report-2016-2014-data
- 265 (accessed Feb 12, 2020).
- 5. Lee SH. The SARS epidemic in Hong Kong. J Epidemiol Community
   Health2003; 57: 652–54.
- Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and
   pathogenesis of coronaviruses. Tr ends Microbiol 2016; 24: 490–502.
- 270 7. Cavanagh D. Coronavirus avian infectious bronchitis virus. Vet Res2007;
  271 38: 281–97.

272	8. Ismail MM, Tang AY, Saif YM. Pathogenicity of turkey coronavirus in
273	turkeys and chickens. Avian Dis 2003; 47: 515–22.
274	9. Zhou P, Fan H, Lan T, et al. Fatal swine acute diarrhoea syndrome caused
275	by an HKU2-related coronavirus of bat origin. Nature 2018; 556: 255–58.
276	10. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat
277	Med 2004; 10 (suppl 12): S88–97.
278	11. Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology 2003; 8 (suppl):
279	S9–14.
280	12. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA.
281	Isolation of a novel coronavirus from a man with pneumonia in Saudi
282	Arabia. N Engl J Med 2012; 367: 1814–20.
283	13. Lee J, Chowell G, Jung E. A dynamic compartmental model for the Middle
284	East respiratory syndrome outbreak in the Republic of Korea: a
285	retrospective analysis on control interventions and superspreading events.
286	J Theor Biol 2016; 408: 118–26.
287	14. Lee JY, Kim YJ, Chung EH, et al. The clinical and virological features of
288	the first imported case causing MERS-CoV outbreak in South Korea, 2015.
289	BMC Infect Dis 2017; 17: 498.
290	15. Tan W, Zhao X, Ma X, et al. A novel coronavirus genome identified in a
291	cluster of pneumonia cases—Wuhan, China 2019-2020. China CDC

292 Weekly 2020; 2: 61–62.

293	16. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with
294	pneumonia in China, 2019. N Engl J Med 2020; published online Jan 24.
295	DOI:10.1056/NEJMoa2001017.
296	
297	Declaration of Interests
298	All the authors of this manuscript declare that there is no conflict of interest.
299	
300	
301	
302	
303	
304	
305	
306	
307	
308	
309	
310	
311	
312	
313	
314	

# **Table 1: Primers used for LAMP and RT-LAMP**

Gene of Interest	Sequence		
N gene	F3-GCCAAAAGGCTTCTACGCA		
	B3-TTGCTCTCAAGCTGGTTCAA		
	FIP-TCCCCTACTGCTGCCTGGAG-CGGCAGTCAAGCCTCTTC		
	BIP-TTCTCCTGCTAGAATGGCTGGC-TCTGTCAAGCAGCAGCAAAG		
	LF-CGACTACGTGATGAGGAACGA		
	LB-AATGGCGGTGATGCTGCTCTT		
ORF gene	F3-TGCTTCAGTCAGCTGATG		
	B3-TTAAATTGTCATCTTCGTCCTT		
	FIP-TCAGTACTAGTGCCTGTGCCCACAATCGTTTTTAAACGGGT		
	BIP-TCGTATACAGGGCTTTTGACATCTATCTTGGAAGCGACAACAA		
	LF-CTGCACTTACACCGCAA		
	LB-GTAGCTGGTTTTGCTAAATTCC		
RNaseP	F3-GTTTCTGAACTCTTCACAACTT		
	B3-TCTAAATGTGTGCAAGCAATA		
	FIP-AGATGGATCCGAGACAATAATTGTTAATTGTACAGGGAAAATCAAGA		
	BIP-TGCAATGTTTTGAGAGCAACTTCGAAAAAGCTTTTCTGTCTTTGG		
	LB-GGGCCCGGCTCTATGAT		

# 319 Table 2: Cycle Threshold Values

S.	Name of the Target	Copy Number of Target	Cycle Threshold (Ct)
No.	RNA	RNA	Value
1	Ν	10 <sup>7</sup>	14.13
		10 <sup>6</sup>	15.42
		10 <sup>5</sup>	18.20
		10 <sup>4</sup>	20.16
		10 <sup>3</sup>	24.56
		10 <sup>2</sup>	28.61
		10 <sup>1</sup>	34.36
2	ORF	10 <sup>7</sup>	14.02
		10 <sup>6</sup>	15.62
		10 <sup>5</sup>	17.38
		10 <sup>4</sup>	18.69
		10 <sup>3</sup>	21.99
		10 <sup>2</sup>	28.22
		10 <sup>1</sup>	33.41
3	RNaseP	10 <sup>7</sup>	21.26
		10 <sup>6</sup>	23.80
		10 <sup>5</sup>	25.13
		10 <sup>4</sup>	26.88
		10 <sup>3</sup>	30.07
		10 <sup>2</sup>	32.62
		10 <sup>1</sup>	No CT

321 Figure 1







1:  $10^7$  copies of *N* gene; 2:  $10^6$  copies of *N* gene; 3:  $10^5$  copies of *N* gene;

A. N Gene

4:  $10^4$  copies of *N* gene; 5.  $10^3$  copies of *N* gene; 6:  $10^2$  copies of *N* gene;

<sup>336</sup> 7: 10<sup>1</sup> copies of *N* gene; 8: No Template Control

- 337
- 338
- 225
- 339



348

- 1:  $10^7$  copies of RP gene; 2:  $10^6$  copies RP gene; 3:  $10^5$  copies of RP gene;
- 4:  $10^4$  copies of RP gene; 5.  $10^3$  copies of RP gene; 6:  $10^2$  copies of RP gene;
- <sup>351</sup> 7: 10<sup>1</sup> copies of RP gene; 8: No Template Control

352

## C. RNaseP (RP) Gene